Rinvoq bags FDA green light
In the SELECT programme, the oral JAK inhibitor met all primary and ranked secondary endpoints across a variety of rheumatoid arthritis patients. - News - PharmaTimes
by Anna Smith
https://www.pharmatimes.com/news/rinvoq_bags_fda_green_light_1298039